Intermittent Parathyroid Hormone Administration Counteracts the Adverse Effects of Glucocorticoids on Osteoblast and Osteocyte Viability, Bone Formation, and Strength in Mice
- 21 April 2010
- journal article
- other
- Published by The Endocrine Society in Endocrinology
- Vol. 151 (6), 2641-2649
- https://doi.org/10.1210/en.2009-1488
Abstract
Glucocorticoids act directly on bone cells to decrease production of osteoblasts and osteoclasts, increase osteoblast and osteocyte apoptosis, and prolong osteoclast life span. Conversely, daily injections of PTH decrease osteoblast and osteocyte apoptosis and increase bone formation and strength. Using a mouse model, we investigated whether the recently demonstrated efficacy of PTH in glucocorticoid-induced bone disease results from the ability of this therapeutic modality to counteract at least some of the direct effects of glucocorticoids on bone cells. Glucocorticoid administration to 5- to 6-month-old Swiss-Webster mice for 28 d increased the prevalence of osteoblast and osteocyte apoptosis and decreased osteoblast number, activation frequency, and bone formation rate, resulting in reduced osteoid, wall and trabecular width, bone mineral density, and bone strength. In contrast, daily injections of PTH caused a decrease in osteoblast and osteocyte apoptosis and an increase in osteoblast number, activation frequency, bone formation rate, bone mineral density, and bone strength. The decreased osteocyte apoptosis was associated with increased bone strength. When the two agents were combined, all the adverse effects of glucocorticoid excess on bone were prevented. Likewise, in cultured osteoblastic cells, PTH attenuated the adverse effects of glucocorticoids on osteoblast survival and Wnt signaling via an Akt phosphorylation-dependent mechanism. We conclude that intermittent PTH administration directly counteracts the key pathogenetic mechanisms of glucocorticoid excess on bone, thus providing a mechanistic explanation of its efficacy against glucocorticoid-induced osteoporosis.Keywords
This publication has 47 references indexed in Scilit:
- Glucocorticoids, osteocytes, and skeletal fragility: The role of bone vascularityBone, 2010
- Endogenous glucocorticoids decrease skeletal angiogenesis, vascularity, hydration, and strength in aged miceAging Cell, 2010
- Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient miceJournal of Bone and Mineral Research, 2010
- Inhibition of glycogen synthase kinase-3β attenuates glucocorticoid-induced bone lossLife Sciences, 2009
- Parathyroid hormone signaling through low-density lipoprotein-related protein 6Genes & Development, 2008
- Glucocorticoid‐induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralizationArthritis & Rheumatism, 2008
- Skeletal Involution by Age-associated Oxidative Stress and Its Acceleration by Loss of Sex SteroidsJournal of Biological Chemistry, 2007
- Molecular and cellular mechanisms of the anabolic effect of intermittent PTHBone, 2007
- Lifelong accumulation of bone in mice lacking Pten in osteoblastsProceedings of the National Academy of Sciences of the United States of America, 2007
- Parathyroid Hormone Stimulates Receptor Activator of NFκB Ligand and Inhibits Osteoprotegerin Expression via Protein Kinase A Activation of cAMP-response Element-binding ProteinJournal of Biological Chemistry, 2002